Intratracheal transplantation of trophoblast stem cells attenuates acute lung injury in mice.
Acute lung injury
Alveolar epithelial cells
Engraftment
Inflammation
Trophoblast stem cells
Journal
Stem cell research & therapy
ISSN: 1757-6512
Titre abrégé: Stem Cell Res Ther
Pays: England
ID NLM: 101527581
Informations de publication
Date de publication:
30 08 2021
30 08 2021
Historique:
received:
07
04
2021
accepted:
08
08
2021
entrez:
31
8
2021
pubmed:
1
9
2021
medline:
30
10
2021
Statut:
epublish
Résumé
Acute lung injury (ALI) is a common lung disorder that affects millions of people every year. The infiltration of inflammatory cells into the lungs and death of the alveolar epithelial cells are key factors to trigger a pathological cascade. Trophoblast stem cells (TSCs) are immune privileged, and demonstrate the capability of self-renewal and multipotency with differentiation into three germ layers. We hypothesized that intratracheal transplantation of TSCs may alleviate ALI. ALI was induced by intratracheal delivery of bleomycin (BLM) in mice. After exposure to BLM, pre-labeled TSCs or fibroblasts (FBs) were intratracheally administered into the lungs. Analyses of the lungs were performed for inflammatory infiltrates, cell apoptosis, and engraftment of TSCs. Pro-inflammatory cytokines/chemokines of lung tissue and in bronchoalveolar lavage fluid (BALF) were also assessed. The lungs displayed a reduction in cellularity, with decreased CD45 Intratracheal transplantation of TSCs into the lungs of mice after acute exposure to BLM reduced pulmonary inflammation and cell death. Furthermore, TSCs engrafted into the alveolar walls to form alveolar epithelial type I and II cells. These data support the use of TSCs for the treatment of ALI.
Sections du résumé
BACKGROUND
Acute lung injury (ALI) is a common lung disorder that affects millions of people every year. The infiltration of inflammatory cells into the lungs and death of the alveolar epithelial cells are key factors to trigger a pathological cascade. Trophoblast stem cells (TSCs) are immune privileged, and demonstrate the capability of self-renewal and multipotency with differentiation into three germ layers. We hypothesized that intratracheal transplantation of TSCs may alleviate ALI.
METHODS
ALI was induced by intratracheal delivery of bleomycin (BLM) in mice. After exposure to BLM, pre-labeled TSCs or fibroblasts (FBs) were intratracheally administered into the lungs. Analyses of the lungs were performed for inflammatory infiltrates, cell apoptosis, and engraftment of TSCs. Pro-inflammatory cytokines/chemokines of lung tissue and in bronchoalveolar lavage fluid (BALF) were also assessed.
RESULTS
The lungs displayed a reduction in cellularity, with decreased CD45
CONCLUSION
Intratracheal transplantation of TSCs into the lungs of mice after acute exposure to BLM reduced pulmonary inflammation and cell death. Furthermore, TSCs engrafted into the alveolar walls to form alveolar epithelial type I and II cells. These data support the use of TSCs for the treatment of ALI.
Identifiants
pubmed: 34461993
doi: 10.1186/s13287-021-02550-z
pii: 10.1186/s13287-021-02550-z
pmc: PMC8404310
doi:
Substances chimiques
Lipopolysaccharides
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
487Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL130275
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI138318
Pays : United States
Organisme : NIH HHS
ID : U01AI38318
Pays : United States
Informations de copyright
© 2021. The Author(s).
Références
Am J Physiol Lung Cell Mol Physiol. 2008 Sep;295(3):L379-99
pubmed: 18621912
Blood Adv. 2020 Oct 13;4(19):4965-4979
pubmed: 33049055
J Aerosol Med Pulm Drug Deliv. 2010 Aug;23(4):243-52
pubmed: 20073554
Sci Rep. 2017 Jul 17;7(1):5575
pubmed: 28717241
Stem Cell Res Ther. 2020 Feb 13;11(1):55
pubmed: 32054514
Nat Biotechnol. 2014 Mar;32(3):252-60
pubmed: 24561556
Am J Physiol Lung Cell Mol Physiol. 2017 Aug 1;313(2):L313-L327
pubmed: 28450283
Life Sci. 2019 Aug 1;230:208-217
pubmed: 31152815
Ann Intensive Care. 2014 Jul 03;4:22
pubmed: 25593740
Sci Rep. 2017 Mar 15;7:44376
pubmed: 28295048
Crit Care Med. 2010 Aug;38(8):1733-41
pubmed: 20562701
Front Bioeng Biotechnol. 2020 Dec 17;8:610544
pubmed: 33392174
Stem Cells. 2011 Jun;29(6):913-9
pubmed: 21506195
Stem Cells. 2013 Feb;31(2):397-407
pubmed: 23132816
Transl Res. 2012 Apr;159(4):205-17
pubmed: 22424425
N Engl J Med. 2017 Nov 9;377(19):1904-1905
pubmed: 29117492
Part Fibre Toxicol. 2014 Dec 13;11:69
pubmed: 25497724
PLoS One. 2017 Jan 20;12(1):e0170561
pubmed: 28107543
Best Pract Res Clin Obstet Gynaecol. 2016 Feb;31:13-29
pubmed: 26547389
Mol Med Rep. 2020 Aug;22(2):1458-1466
pubmed: 32626979
Cell Physiol Biochem. 2015;35(6):2149-58
pubmed: 25896232
Am J Physiol Lung Cell Mol Physiol. 2014 Jan;306(2):L152-61
pubmed: 24285266
Stem Cells Int. 2018 Jan 18;2018:4837930
pubmed: 29535770
Mol Ther. 2012 Dec;20(12):2335-46
pubmed: 22968480
Curr Opin Toxicol. 2019 Feb;13:68-73
pubmed: 31289762
Stem Cells Int. 2012;2012:709763
pubmed: 22577395
Cell Death Discov. 2019 Feb 8;5:63
pubmed: 30774991
Lancet Respir Med. 2015 Jan;3(1):24-32
pubmed: 25529339
APMIS. 2012 Oct;120(10):808-18
pubmed: 22958289
Am J Physiol Lung Cell Mol Physiol. 2005 Oct;289(4):L521-8
pubmed: 16148050
Ann N Y Acad Sci. 2019 Feb;1437(1):15-21
pubmed: 29740848
N Engl J Med. 2005 Oct 20;353(16):1685-93
pubmed: 16236739
Mucosal Immunol. 2014 May;7(3):684-93
pubmed: 24172847
Crit Care Clin. 2011 Apr;27(2):355-77
pubmed: 21440206
Br Med Bull. 2013;105:43-68
pubmed: 23184854
Am J Physiol Lung Cell Mol Physiol. 2008 Feb;294(2):L152-60
pubmed: 17993587
Sci Adv. 2020 Jul 22;6(30):eaba6884
pubmed: 32832666
Exp Lung Res. 2015 Mar;41(2):57-73
pubmed: 25514507
Mol Ther. 2010 Mar;18(3):625-34
pubmed: 20087316
J Interferon Cytokine Res. 2009 Jun;29(6):313-26
pubmed: 19441883
Cell Transplant. 2011;20(6):909-23
pubmed: 21092408
Respiration. 2011;82(3):273-87
pubmed: 21659722
Thorax. 1987 Jul;42(7):551-2
pubmed: 2449743